Beren clinches long-awaited FDA nod for cyclodextrin drug in Niemann-Pick disease

road through forest
The FDA based its long-awaited decision on an overall survival analysis from three trials of Beren's drug. (iStock/Getty Images Plus)

Beren Therapeutics has officially seen a cyclodextrin therapy across the finish line, scoring an FDA approval in Niemann-Pick disease type C (NPC) that’s over a decade in the making. 

The agency gave the go-ahead on Tuesday, approving Beren's adrabetadex under the brand name Lembaz for both adults and children with NPC whose neurological symptoms started before age 6. With the new regulatory clearance, Lembaz becomes the first medicine shown to both improve infant NPC survival and to target the cholesterol transport issues underlying the condition, Beren said in a Nov. 17 release. 

Faulty cholesterol transport is the hallmark of NPC, a rare and devastating genetic disorder marked by neurological decline and premature death. In patients with the condition, malfunctioned proteins are unable to properly use and distribute fats across cells, causing the lipids to build up to the point of cellular damage that becomes most severe in the brain and nervous system.  

Scientists have known that cyclodextrin-based treatment had real potential in NPC since 2009, when preclinical data first showed the investigational treatment could delay NPC onset and extend survival in mice. But the road to approval has been laden with setbacks. 

A phase 2/3 trial on the asset now approved as Lembaz was launched in 2015, and the molecule weathered a series of acquisitions before it failed in 2018 under Mallinckrodt ownership. Beren acquired the asset in 2021 as part of Mallinckrodt’s bankruptcy sale and found a path to file for FDA approval in late 2025.

But setbacks continued as recently as this year, when the FDA delayed its original Aug. 17 decision target by three months. The extra wait came after Beren responded to the agency’s request for additional data, which the FDA classified as a major amendment, in turn extending its review timeline.

The FDA has now based its decision on an overall survival analysis from three trials. The analysis showed that treatment with Lembaz reduced the risk of mortality by 55% in patients with infantile-onset NPC compared to an external control arm.

“For the first time, Lembaz gives clinicians a way to address the underlying cholesterol trafficking defect that causes infantile-onset NPC, where early intervention can make the greatest difference,” Elizabeth Berry-Kravis, M.D., Ph.D., lead investigator of the Lembaz expanded access program, said in a statement. 

For families, Heather Moran-Teal, executive director of the National Niemann Pick Disease Foundation, said that “these encouraging survival findings carry profound meaning and hope for more time together.” 

Beren said in a statement that Lembaz will be available at commercial sites nationwide by early December. Families will work directly with a Beren Family Access Manager (FAM) to find an appropriate treatment site. The drugmaker also said its committed to financial support covering out-of-pocket costs for eligible families and providing dedicated case managers to help navigate coverage. 

Lembaz marks the FDA’s third approval for NPC after IntraBio’s Aqneursa and Zevra’s Miplyffa were approved in the same month in 2024. Japan's Shionogi stepped in to purchase IntraBio and its medicine in October. 

To Lembaz’s advantage, it’s the only treatment approved based on survival data. The other two treatments were cleared on data showing they improved disease progression and neurological function. Lembaz is also indicated for the smallest of patients starting at 15 pounds compared to 33 pounds with Aqneursa and two years of age with Miplyffa.